Breakpoints
The SIDP Podcast

What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

Ryan Shields and Erin McCreary discuss notable infectious diseases publications from the first half of 2020.

Papers discussed:

1) Van Duin D, et al. Lancet Infect Dis. 2020 Jun;20(6):731-741. doi: 10.1016/S1473-3099(19)30755-8. 2) Livermore DM, et al. Clin Infect Dis. 2020 Feb 6;ciaa122. doi: 10.1093/cid/ciaa122. 3) Falcone M, et al. Clin Infect Dis. 2020 May 19;ciaa586. doi: 10.1093/cid/ciaa586. 4) Lodise TP, et al. J Antimicrob Chemother. 2020 May 28;dkaa197. doi: 10.1093/jac/dkaa197. 5) O’Donnell JN, et al. Clin Ther. 2020 Jul 16;S0149-2918(20)30315-5. doi: 10.1016/j.clinthera.2020.06.005. 6) Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. 7) Cusumano JA, et al. Am J Health Syst Pharm. 2020 Jul 7;77(14):1104-1112. doi: 10.1093/ajhp/zxaa128. 8) Roberts JA, et al. Clin Infect Dis. 2020 Mar 9;ciaa224. doi: 10.1093/cid/ciaa224. 9) Ackerman A, et al. Antimicrob Agents Chemother. 2020 May 21;64(6):e00066-20. doi: 10.1128/AAC.00066-20. 10) Tong SYC, et al. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. 11) Jones BE, et al. JAMA Intern Med. 2020 Feb 17;180(4):552-560. doi: 10.1001/jamainternmed.2019.7495. 12) Cheng MP, et al. Clin Infect Dis. 2020 Jul 15;ciaa1000. doi: 10.1093/cid/ciaa1000.

For BCIDP credit, visit https://sidp.org/BCIDP

Follow SIDP on Twitter: @SIDPharm

What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

Ryan Shields and Erin McCreary discuss notable infectious diseases publications from the first half of 2020!

Papers discussed:

1) Rybak MJ, et al. Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036. 2) Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076. 3) Alosaimy S, et al. Clin Infect Dis. 2020 July 27;ciaa1039. doi: 10.1093/cid/ciaa1039. 4) Rhee C, et al. Clin Infect Dis. 2020 May 6;ciaa059. doi: 10.1093/cid/ciaa059. 5) Heil EL, et al. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384. 6) Townsend SR, et al. Clin Infect Dis. 2020 May 6;ciaa458. doi: 10.1093/cid/ciaa458. 7) Satlin MJ, et al. Clin Infect Dis. 2020 Feb 13;ciaa121. doi: 10.1093/cid/ciaa121. 8) Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19. 9) Ambrose PG, et al. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084. 10) Singh N, et al. JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138. 11) van Delden C, et al. Clin Infect Dis. 2020 Jan 9;ciz1113. doi: 10.1093/cid/ciz1113. 12) Niederman MS, et al. Lancet Infect Dis. 2020 Mar;20(3):330-340. doi: 10.1016/S1473-3099(19)30574-2. 13) von Dach E, et al. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348. 14) Mergenhagen KA, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02167-19. doi: 10.1128/AAC.02167-19.

For BCIDP credit, visit https://sidp.org/BCIDP

Follow SIDP on Twitter: @SIDPharm

Expert Updates in Gram Negative Resistance: Q&A Session

This is part 2 of a continuing education series produced in partnership with the SIDP Education Center (SIDPEC) on gram-negative bacterial resistance. It features expert speakers, Drs. Keith Kaye and Kimberly Claeys. If you missed part 1 of this series, delivered as a webinar lecture, please go to sidp.org/SIDPEC to view that portion of the series first. In this podcast, our experts answer a collation of > 150 questions from interested viewers on the nuances of gram-negative bacterial resistance, from real-world formulary considerations to microbiology lab implementation and more.

OPAT - The Final Frontier, Part 2

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine, Monica Mahoney, Keenan Ryan, Monica Donnelley, and Meera Mehta.

Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

Drs. Julie Ann Justo, Erin McCreary, and Helen Newland discuss ethical allocation of Emergency Use Authorization remdesivir for patients with COVID-19

OPAT – The Final Frontier, Part 1

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine, Monica Mahoney, Keenan Ryan, Monica Donnelley, and Meera Mehta.

Taking a “BITE” Out of Antibiotic Prescribing: Strategies to Improve Antimicrobial Usage in Dentistry

Dr. Katie Suda and Dr. Erinne Kennedy join Dr. Zahra Escobar of the Breakpoints team to discuss strategies to improve antibiotic utilization and forge connections with our dental colleagues to achieve a common goal of improved patient outcomes.

Taking a “BITE” Out of Antibiotic Prescribing: The Need for Antimicrobial Stewardship in Dentistry

Dr. Katie Suda and Dr. Erinne Kennedy join Dr. Zahra Escobar of the Breakpoints team to discuss why dentists prescribe 1 in 10 of all antibiotics in the United States and how COVID-19 risks are being managed among dentists and other oral health providers.

Frontline Allies: Emergency Medicine and Critical Care Insights into COVID19

Dr. Jenny Koehl, Dr. Karen Berger, and Dr. Karen Dohr join the Breakpoints team to discuss taking care of patients with COVID-19 in the Emergency Department and Intensive Care Unit. Listen as the team reflects on their first patients, PPE, anticoagulation, corticosteroid controversies, and more!

What is Happening Right Now? COVID-19 Challenges and Silver Linings

Julie Justo, Jason Pogue, and Erin McCreary discuss critically evaluating COVID-19 literature, staying calm in the storm, strategies for team education and communication, and the role of social media in a pandemic.